TY - JOUR T1 - Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma JF - American Journal of Neuroradiology JO - Am. J. Neuroradiol. SP - 2201 LP - 2208 DO - 10.3174/ajnr.A4898 VL - 37 IS - 12 AU - H.S. Nguyen AU - N. Milbach AU - S.L. Hurrell AU - E. Cochran AU - J. Connelly AU - J.A. Bovi AU - C.J. Schultz AU - W.M. Mueller AU - S.D. Rand AU - K.M. Schmainda AU - P.S. LaViolette Y1 - 2016/12/01 UR - http://www.ajnr.org/content/37/12/2201.abstract N2 - BACKGROUND AND PURPOSE: Patients with recurrent glioblastoma often exhibit regions of diffusion restriction following the initiation of bevacizumab therapy. Studies suggest that these regions represent either diffusion-restricted necrosis or hypercellular tumor. This study explored postmortem brain specimens and a population analysis of overall survival to determine the identity and implications of such lesions.MATERIALS AND METHODS: Postmortem examinations were performed on 6 patients with recurrent glioblastoma on bevacizumab with progressively growing regions of diffusion restriction. ADC values were extracted from regions of both hypercellular tumor and necrosis. A receiver operating characteristic analysis was performed to define optimal ADC thresholds for differentiating tissue types. A retrospective population study was also performed comparing the overall survival of 64 patients with recurrent glioblastoma treated with bevacizumab. Patients were separated into 3 groups: no diffusion restriction, diffusion restriction that appeared and progressed within 5 months of bevacizumab initiation, and delayed or stable diffusion restriction. An additional analysis was performed assessing tumor O6-methylguanine-DNA-methyltransferase methylation.RESULTS: The optimal ADC threshold for differentiation of hypercellularity and necrosis was 0.736 × 10−3mm2/s. Progressively expanding diffusion restriction was pathologically confirmed to be coagulative necrosis surrounded by viable tumor. Progressive lesions were associated with the worst overall survival, while stable lesions showed the greatest overall survival (P < .05). Of the 40% of patients with O6-methylguanine-DNA-methyltransferase methylated tumors, none developed diffusion-restricted lesions.CONCLUSIONS: Progressive diffusion-restricted lesions were pathologically confirmed to be coagulative necrosis surrounded by viable tumor and associated with decreased overall survival. Stable lesions were, however, associated with increased overall survival. All lesions were associated with O6-methylguanine-DNA-methyltransferase unmethylated tumors.GBMglioblastomaMGMTO6-methylguanine-DNA-methyltransferaseOSoverall survival ER -